C5AR1 and Huntington disease: Administration of C5aR antagonists (PMX53 and PMX205) either pre- or post-3-NP induction reduced HD phenotypes; including weight loss and motor deficits such as ataxia and dystonia [146], suggesting a role for complement-driven inflammation in the disease process.